Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center Identifier:
First received: May 6, 2003
Last updated: January 14, 2014
Last verified: January 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2004
  Primary Completion Date: March 2003 (Final data collection date for primary outcome measure)